

Andreas Munk Petersen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7434919/publications.pdf>

Version: 2024-02-01

45
papers

1,873
citations

361045

20
h-index

276539

41
g-index

49
all docs

49
docs citations

49
times ranked

2980
citing authors

#	ARTICLE	IF	CITATIONS
1	Substantial Decrease in Vancomycin-Resistant <i>Enterococcus faecium</i> Outbreak Duration and Number of Patients During the Danish COVID-19 Lockdown: A Prospective Observational Study. <i>Microbial Drug Resistance</i> , 2022, 28, 73-80.	0.9	12
2	Long-Term Safety Following Faecal Microbiota Transplantation as a Treatment for Recurrent <i>Clostridioides difficile</i> Infection Compared with Patients Treated with a Fixed Bacterial Mixture: Results from a Retrospective Cohort Study. <i>Cells</i> , 2022, 11, 435.	1.8	8
3	Bacteraemia caused by <i>Lactobacillus rhamnosus</i> given as a probiotic in a patient with a central venous catheter: a WGS case report. <i>Infection Prevention in Practice</i> , 2022, 4, 100200.	0.6	7
4	Substantial Intestinal Microbiota Differences Between Patients With Ulcerative Colitis From Ghana and Denmark. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 832500.	1.8	4
5	The use of core genome multilocus sequence typing to determine the duration of vancomycin-resistant <i>Enterococcus faecium</i> outbreaks. <i>Apmis</i> , 2022, 130, 323-329.	0.9	4
6	Successful treatment of <i>Clostridioides difficile</i> infection with single-donor faecal microbiota transplantation capsules. <i>Danish Medical Journal</i> , 2022, 69, .	0.5	0
7	No Effect of <i>Lactobacillus rhamnosus</i> GG on Eradication of Colonization by Vancomycin-Resistant <i>Enterococcus faecium</i> or Microbiome Diversity in Hospitalized Adult Patients. <i>Microbiology Spectrum</i> , 2022, 10, e0234821.	1.2	5
8	Engraftment of strictly anaerobic oxygen-sensitive bacteria in irritable bowel syndrome patients following fecal microbiota transplantation does not improve symptoms. <i>Gut Microbes</i> , 2021, 13, 1-16.	4.3	8
9	Pre-clinical evaluation of the effect of co-medication with antibiotics and oral steroids in GÅttingen Minipigs on the biological activity of the probiotic medicinal product TSO (<i>Trichuris suis ova</i>). <i>Parasitology Research</i> , 2021, 120, 743-746.	0.6	0
10	A21 ULCERATIVE COLITIS-ASSOCIATED <i>E. COLI</i> PATHOBIONTS POTENTIATE COLITIS IN SUSCEPTIBLE HOSTS. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, 142-144.	0.1	0
11	Fecal microbiota transplantation in hepatic encephalopathy: a systematic review. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 560-569.	0.6	26
12	The effect of faecal microbiota transplantation on abdominal pain, stool frequency, and stool form in patients with moderate-to-severe irritable bowel syndrome: results from a randomised, double-blind, placebo-controlled study. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 761-769.	0.6	15
13	Systematic review with meta-analysis: encapsulated faecal microbiota transplantation "evidence for clinical efficacy. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110410.	1.4	18
14	Randomised clinical trial: a 12-strain bacterial mixture versus faecal microbiota transplantation versus vancomycin for recurrent <i>Clostridioides difficile</i> infections. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 999-1009.	1.9	25
15	Fecal Microbiota Transplantation in the Treatment of Chronic Pouchitis: A Systematic Review. <i>Microorganisms</i> , 2020, 8, 1433.	1.6	16
16	Ulcerative Colitis-associated <i>E. coli</i> pathobionts potentiate colitis in susceptible hosts. <i>Gut Microbes</i> , 2020, 12, 1847976.	4.3	26
17	Effect of β -Hemolysin Producing <i>E. coli</i> in Two Different Mouse Strains in a DSS Model of Inflammatory Bowel Disease. <i>Microorganisms</i> , 2020, 8, 1971.	1.6	5
18	Multistrain Probiotic Increases the Gut Microbiota Diversity in Obese Pregnant Women: Results from a Randomized, Double-Blind Placebo-Controlled Study. <i>Current Developments in Nutrition</i> , 2020, 4, nzaa095.	0.1	24

#	ARTICLE	IF	CITATIONS
19	High Abundance of Proteobacteria in Ileo-Anal Pouch Anastomosis and Increased Abundance of Fusobacteria Associated with Increased Pouch Inflammation. <i>Antibiotics</i> , 2020, 9, 237.	1.5	11
20	Association between vancomycin-resistant <i>Enterococcus faecium</i> colonization and subsequent infection: a retrospective WGS study. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1712-1715.	1.3	11
21	Persistence of antibodies to pneumococcal conjugate vaccine compared to polysaccharide vaccine in patients with Crohn's disease – one year follow up. <i>Infectious Diseases</i> , 2019, 51, 651-658.	1.4	5
22	Increased abundance of proteobacteria in aggressive Crohn's disease seven years after diagnosis. <i>Scientific Reports</i> , 2019, 9, 13473.	1.6	83
23	<i>Escherichia coli</i> Pathobionts Associated with Inflammatory Bowel Disease. <i>Clinical Microbiology Reviews</i> , 2019, 32, .	5.7	194
24	Multidonor FMT capsules improve symptoms and decrease fecal calprotectin in ulcerative colitis patients while treated – an open-label pilot study. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 289-296.	0.6	33
25	Characterization of the enhancer and promoter landscape of inflammatory bowel disease from human colon biopsies. <i>Nature Communications</i> , 2018, 9, 1661.	5.8	78
26	The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon. <i>Mucosal Immunology</i> , 2018, 11, 449-461.	2.7	31
27	Case series of successful treatment with fecal microbiota transplant (FMT) oral capsules mixed from multiple donors even in patients previously treated with FMT enemas for recurrent <i>Clostridium difficile</i> infection. <i>Medicine (United States)</i> , 2018, 97, e11706.	0.4	15
28	Stability and resilience of the intestinal microbiota in children in daycare – a 12-month cohort study. <i>BMC Microbiology</i> , 2018, 18, 223.	1.3	15
29	Characterization of Diarrheagenic Enteroaggregative <i>Escherichia coli</i> in Danish Adults – Antibiotic Treatment Does Not Reduce Duration of Diarrhea. <i>Frontiers in Cellular and Infection Microbiology</i> , 2018, 8, 306.	1.8	22
30	Review of <i>Saccharomyces boulardii</i> as a treatment option in IBD. <i>Immunopharmacology and Immunotoxicology</i> , 2018, 40, 465-475.	1.1	33
31	Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. <i>Gut</i> , 2018, 67, 2107-2115.	6.1	250
32	Use of prophylactic <i>Saccharomyces boulardii</i> to prevent <i>Clostridium difficile</i> infection in hospitalized patients: a controlled prospective intervention study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 1431-1439.	1.3	13
33	Can fecal microbiota transplantation cure irritable bowel syndrome?. <i>World Journal of Gastroenterology</i> , 2017, 23, 4112.	1.4	51
34	Effects of probiotics (Vivomixx®) in obese pregnant women and their newborn: study protocol for a randomized controlled trial. <i>Trials</i> , 2016, 17, 491.	0.7	26
35	Extraintestinal pathogenic <i>Escherichia coli</i> are associated with intestinal inflammation in patients with ulcerative colitis. <i>Scientific Reports</i> , 2016, 6, 31152.	1.6	33
36	Childhood diarrhoea in Danish day care centres could be associated with infant colic, low birthweight and antibiotics. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2016, 105, 90-95.	0.7	8

#	ARTICLE	IF	CITATIONS
37	Secretion of Alpha-Hemolysin by <i>Escherichia coli</i> Disrupts Tight Junctions in Ulcerative Colitis Patients. <i>Clinical and Translational Gastroenterology</i> , 2016, 7, e149.	1.3	45
38	Distinct inflammatory and cytopathic characteristics of <i>Escherichia coli</i> isolates from inflammatory bowel disease patients. <i>International Journal of Medical Microbiology</i> , 2015, 305, 925-936.	1.5	27
39	Antibiotic treatment of verocytotoxin-producing <i>Escherichia coli</i> (VTEC) infection: a systematic review and a proposal. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2440-2446.	1.3	51
40	Immunosuppressive drugs impairs antibody response of the polysaccharide and conjugated pneumococcal vaccines in patients with Crohn's disease. <i>Vaccine</i> , 2015, 33, 5464-5469.	1.7	40
41	Intestinal colonization with phylogenetic group B2 <i>Escherichia coli</i> related to inflammatory bowel disease: a systematic review and meta-analysis. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 1199-1207.	0.6	24
42	Inflammatory Bowel Disease Patients Are at Increased Risk of Invasive Pneumococcal Disease: A Nationwide Danish Cohort Study 1977-2013. <i>American Journal of Gastroenterology</i> , 2015, 110, 1582-1587.	0.2	77
43	Epidemiology and Clinical Manifestations of Enteraggregative <i>Escherichia coli</i> . <i>Clinical Microbiology Reviews</i> , 2014, 27, 614-630.	5.7	163
44	Ciprofloxacin and probiotic <i>Escherichia coli</i> Nissle add-on treatment in active ulcerative colitis: A double-blind randomized placebo controlled clinical trial. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1498-1505.	0.6	101
45	Virulence Factors for Hemolytic Uremic Syndrome, Denmark1. <i>Emerging Infectious Diseases</i> , 2004, 10, 842-847.	2.0	228